Skip to content
DataLookout
Start free
Menu

RESANCT06767891

Real-world Study of Acalabrutinib

StatusEnrolling by Invitation
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 3 years 2 months later, enrollment reduced 20%.

See at-risk trials from Ruijin Hospital

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 30, 2026 to Oct 2029v2 Show 5 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Enrollment reduced: 200 → 160 participants
    • Study completion pushed from Jan 30, 2028 to Nov 2029
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 300 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

treatment patterns
Timeframe: Oct 2029

Secondary (2)

The percentage of patients with AEs, SAEs (safety)
posology

Arms and interventions

MCL

Chinese patients with MCL treated with acalabrutinib

CLL/SLL

Chinese patients with CLL/SLL treated with acalabrutinib

Sites

1 site in 1 country

  • Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, Shanghai Municipality, China